TrialEmerging microbes & infections2022

Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Ji-Min Seo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.